CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 22 enrolled
Drug / intervention
Ranolazine +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01873950
NCT01873950Phase 1Completed

A Double-Blind, Randomized, Placebo-Controlled Single-Dose, Five Period Crossover Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects

Food and Drug Administration (FDA)·interventional·Posted Jun 10, 2013·Updated Mar 8, 2018

In Brief

A Phase 1 clinical trial evaluating Ranolazine, Dofetilide, and 3 other interventions for Drug-induced Surface ECG Changes. Completed, enrolled 22 participants.

Detailed Summary

This study seeks to compare 4 known QT prolonging drugs versus placebo to determine their effects on electrophysiological and other clinical parameters. The underlying purpose is to determine if depolarization and repolarization effects caused by drugs with differing ionic channel mechanisms can be distinguished from one another, and to gauge the sensitivity and specificity of novel signal analyses for detection of depolarization and repolarization changes. Secondarily, to evaluate the exposure response relationship and drug induced effects on the heart rate biomarker relationship.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--

Timeline

Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 10, 2013
Enrollment StartMay 1, 2013
Primary CompletionJul 1, 2013
Study CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 13.1 years ago

Interventions

Ranolazinedrug

Dofetilidedrug

Verapamildrug

Quinidine sulfatedrug

Placebodrug